Technology
Health
Pharmaceutical
Zynerba Pharmaceuticals
$12.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$12.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.19 (1.63%) Today
+$0.15 (1.26%) As of 6:13 PM EDT after-hours
Why Robinhood?
You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!
About ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
246.16M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.67M
High Today
$12.24
Low Today
$11.50
Open Price
$11.95
Volume
1.39M
52 Week High
$16.47
52 Week Low
$2.75
Collections
Technology
Health
Pharmaceutical
Medical
2015 IPO
US
North America
ZYNE News
Price Paid on Robinhood
57% Higher
Right Now
52 Week Low
$2.75
Average Price Paid
$7.66
52 Week High
$12.50
ZYNE Earnings
-$0.91
-$0.75
-$0.60
-$0.44
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, Pre-Market